Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May;13(3):440-450.
doi: 10.1111/cts.12736. Epub 2020 Feb 6.

The Progression of Regenerative Medicine and its Impact on Therapy Translation

Erik Jacques  1   2 , Erik J Suuronen  1   3
Affiliations
Review

The Progression of Regenerative Medicine and its Impact on Therapy Translation

Erik Jacques et al. Clin Transl Sci. 2020 May.

Abstract

Despite regenerative medicine (RM) being one of the hottest topics in biotechnology for the past 3 decades, it is generally acknowledged that the field's performance at the bedside has been somewhat disappointing. This may be linked to the novelty of these technologies and their disruptive nature, which has brought an increasing level of complexity to translation. Therefore, we look at how the historical development of the RM field has changed the translational strategy. Specifically, we explore how the pursuit of such novel regenerative therapies has changed the way experts aim to translate their ideas into clinical applications, and then identify areas that need to be corrected or reinforced in order for these therapies to eventually be incorporated into the standard-of-care. This is then linked to a discussion of the preclinical and postclinical challenges remaining today, which offer insights that can contribute to the future progression of RM.

PubMed Disclaimer

Conflict of interest statement

All authors declared no competing interest for this work.

Figures

Figure 1
Figure 1
A summary timeline of the recent history of regenerative medicine (RM). Selected milestones in the development of RM are presented starting from the 1950s all the way up to the present day.
Figure 2
Figure 2
The negative feedback cycle currently present in most discovery and development processes of regenerative medicine. This cycle obstructs progression of the field.
Figure 3
Figure 3
A comparison between the traditional and modern scientist. Although traditional scientists are more hypothesis‐driven and rigid in terms of research methodology, if the concepts shown above are used, it can generate the modern scientist who is better suited for the translation of regenerative therapies. RM, regenerative medicine.
Figure 4
Figure 4
A comparison of both the royalty and integrated business models used by private companies in the biomedical industry. The pros and cons are listed with the assumption that they are for a start‐up company in regenerative medicine.
Figure 5
Figure 5
Summary of the preclinical and postclinical challenges discussed. Even though preclinical obstacles to the translation of regenerative medicine therapies are more elusive, they are just as significant as their counterparts.
See this image and copyright information in PMC

References

    1. Barker, C.F. & Markmann, J.F. Historical overview of transplantation. Cold Spring Harb. Perspect. Med. 3, 1–18 (2013). - PMC - PubMed
    1. Sampogna, G. , Guraya, S.Y. & Forgione, A. Regenerative medicine: historical roots and potential strategies in modern medicine. J. Microsc. Ultrastruct. 3, 101–107 (2015). - PMC - PubMed
    1. Slingerland, A.S. , Smits, A.I.P.M. & Bouten, C.V.C. Then and now: hypes and hopes of regenerative medicine. Trends Biotechnol. 31, 121–123 (2013). - PubMed
    1. Langer, R. & Vacanti, J.P. Tissue engineering. Science 13260, 920–926 (1993). - PubMed
    1. Greenwood, H.L. , Thorsteinsdottir, H. , Perry, G. , Renihan, J. , Singer, P. & Daar, A. Regenerative medicine: new opportunities for developing countries. Int. J. Biotechnol. 8, 60–77 (2006).

MeSH terms

LinkOut - more resources